Skip to main content
Figure 1 | Parasites & Vectors

Figure 1

From: Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis

Figure 1

Cellular and humoral responses in BALB/c mice immunized with the LmL3 + LmL5 + CpG-ODN combined vaccine. Spleen cell cultures were established four weeks after the last vaccine dose and maintained for 48 h at 37°C, 5% CO2. As control, spleen cell cultures from mice immunized with the vaccine diluent (Saline) and the CpG-ODN adjuvant (CpG) were prepared at the same time. Splenocytes were grown without stimulus (medium; background control) or independently stimulated with the recombinant LmL3 or LmL5 proteins (at 12 μg/ml each one), with Soluble L. major Antigen (LmSLA), L. major Ribosomal Proteins (LmLRP) or Mouse Ribosomal Proteins (MRP) (at 12 μg/ml for each extract). (A) IFN-γ, (B) IL-10 and (C) IL-4 levels were assessed by ELISA in culture supernatants. Each bar represents the mean + standard deviation (SD) of data from five individual mice. * P < 0.05; significant cytokine production increase between LmL3 + LmL5 + CpG-ODN vaccinated mice and both control groups. (D) IgG1 and IgG2a antibodies against LmL3, LmL5, SLA, LRP and MRP were measured in serum samples from the three mice groups. Samples were obtained four weeks after the last vaccine dose and individually tested by ELISA at 1/200 dilution. Each bar represents the mean + SD of data from five individual mice. * P < 0.05; significant increase in the optical density between LmL3 + LmL5 + CpG-ODN vaccinated mice and both control groups. Data shown are representative of at least two independent experiments with similar results.

Back to article page